Chemical Structure : AZD 4320
CAS No.: 1357576-48-7
Catalog No.: PC-61988Not For Human Use, Lab Use Only.
AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.
Packing | Price | Stock | Quantity |
---|---|---|---|
5 mg | $158 | In stock | |
10 mg | $248 | In stock | |
25 mg | $428 | In stock | |
50 mg | Get quote | ||
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.
AZD4320 induces caspase-3 cleavage and cell death in both Bcl-2-driven (SuDHL4, GI50 <50 nM) and Bcl-xL-driven (SuDHL8, GI50 <50 nM) diffuse large B-cell lymphoma (DLBCL) cell lines.
AZD4320 treatment results in complete and sustained (>24 days) tumor regressions in a mouse RS4;11 acute lymphocytic leukemia xenograft model (20 mg/kg, i.v.).
M.Wt | 945.525 | |
Formula | C45H48ClF3N4O7S3 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
4-(4-((R)-(4'-chloro-[1,1'-biphenyl]-2-yl)(hydroxy)methyl)piperidin-1-yl)-N-((4-(((R)-4-((2-hydroxyethyl)(methyl)amino)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide |
1. Ashkenazi A, et al. Nat Rev Drug Discov. 2017 Apr;16(4):273-284.
2. Hennessy, E. J. et al. Discovery of potent inhibitors of the antiapoptotic proteins Bcl-2 and Bcl-xL, resulting in the identification of a clinical candidate for the treatment of cancer (AZD4320). ACS Medicinal Chemistry annual meeting 2015.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright